Spooren, Will

Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice

Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 489

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 336

Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes

Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Spooren, W., Fuss, B., Mallon, B., Macklin, W. B., Fujiwara, H., et al. (2002) · The EMBO Reports

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 314

Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity

Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 308

The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders

Loth, E., Charman, T., Mason, L., Tillmann, J., Jones, E. J. H., Wooldridge, C., Ahmad, J., Auyeung, B., Brogna, C., Ambrosino, S., et al. (2017) · Molecular Autism

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 299

Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism

Baudouin, S. J., Gaudias, J., Gerharz, S., Hatstatt, L., Zhou, K., Punnakkal, P., Tanaka, K. F., Spooren, W., Hen, R., De Zeeuw, C. I., et al. (2012) · Science

Genetics and Neurodevelopmental DisordersAutism Spectrum Disorder Research

Cited by 293

The EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation

Charman, T., Loth, E., Tillmann, J., Crawley, D., Wooldridge, C., Goyard, D., Ahmad, J., Auyeung, B., Ambrosino, S., Banaschewski, T., et al. (2017) · Molecular Autism

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 183

Identification and validation of biomarkers for autism spectrum disorders

Loth, E., Spooren, W., Ham, L. M., Isaac, M. B., Auriche-Benichou, C., Banaschewski, T., Baron-Cohen, S., Broich, K., Bölte, S., Bourgeron, T., et al. (2016) · Nature Reviews Drug Discovery

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 140

Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders

Spooren, W., Lindemann, L., Ghosh, A., & Santarelli, L. (2012) · Trends in Pharmacological Sciences

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 119

CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor

Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 118

Comprehensive analysis of the 16p11.2 deletion and null Cntnap2 mouse models of autism spectrum disorder

Brunner, D., Kabitzke, P., He, D., Cox, K., Thiede, L., Hanania, T., Sabath, E., Alexandrov, V., Saxe, M., Peles, E., et al. (2015) · PLOS ONE

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 111

Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 107

Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 66

European clinical network: autism spectrum disorder assessments and patient characterisation

Ashwood, K. L., Buitelaar, J., Murphy, D., Spooren, W., & Charman, T. (2015) · European Child & Adolescent Psychiatry

Autism Spectrum Disorder ResearchChild Nutrition and Feeding Issues

Cited by 39

Developing new pharmacotherapies for autism

Ecker, C., Spooren, W., & Murphy, D. (2013) · Journal of Internal Medicine

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 31

EU-AIMS Longitudinal European Autism Project (LEAP): the autism twin cohort

the EU-AIMS LEAP group, Isaksson, J., Tammimies, K., Neufeld, J., Cauvet, É., Lundin, K., Buitelaar, J. K., Loth, E., Murphy, D. G. M., Spooren, W., et al. (2018) · Molecular Autism

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 17